Search
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc. … D2.
Categories: Vitamin D and AnaloguesSynonyms: 1-Hydroxyvitamin D2, 1α-hydroxyvitamin D2Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalThe FDA said it is keeping the black box in place at least until the results of the trial are announced. … Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015.
Mixtures: Nra-varenicline, Nra-vareniclineProducts: Nra-vareniclineCetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalManufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same
Metaxalone
go.drugbank.com/drugs/DB00660ApprovedInvestigationalIt is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedIt is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28].
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalMepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases
Copper oxodotreotide Cu-64
go.drugbank.com/drugs/DB15873Approved[A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. … Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over <sup>68</sup>Ga-labeled somatostatin analogs for positron emission tomography (PET).
Synonyms: Copper Cu-64 dotatate, Copper dotatate Cu-64Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.
Fluclorolone acetonide
go.drugbank.com/drugs/DB08973ApprovedWithdrawnIt is marketed under the brand names Cutanit and Topicon.